S_mary The expression of complex carbohydrates recognised by Helix pomatia lectin (HPA, nominal monosaccharide binding specificity alpha-GalNAc) has been shown to predict unfavourable prognosis in breast and other cancers. It has been suggested that the prognostic significance of HPA binding may be through recognition of either Tn epitope (alpha-GaINAc-O-serine threonine) or blood group A antigen (terminal alpha-l-*3GaINAc attached to the basic H-antigen, Fuc-alpha-l+2-Gal-beta-I-*4(or 3) GIcNAc-*R). In this study, the expression of glycoproteins terminating in alpha-GalNAc residues was investigated immunohistochemically using HPA and two monoclonal antibodies -BRIC 66 (anti-alphaGalNAc) and BRIC Ill (anti-Tn 
Altered glycosylation is a common feature in malignancy. Alterations in cell-surface carbohydrates have been related to the metastatic potential of experimental tumours and correlated with highly metastatic cell lines (e.g. Ishikawa et al., 1988; Infusa et al., 1991) . We have demonstrated that binding of a lectin from the Roman snail, Helix pomatia (HPA), to an unidentified carbohydrate ligand in paraffin sections of primary breast cancers is strongly associated with metastases to axillary lymph nodes and distant sites and with consequent poor patient prognosis (Leathem and Brooks, 1987; Brooks and Leathem, 1991) . This observation has been confirmed by several independent studies on breast cancer (Fenlon et al., 1987; Fukutomi et al., 1989; Alam et al., 1990) , and recent reports describe similar findings in gastric cancer (Kakeji et al., 1991) , colorectal cancer (Schumacher et al., 1994) and prostate cancer (Shiraishi et al., 1992) .
HPA recognises alpha-glycosidically linked terminal N-acetylgalactosamine (GalNAc) as in, for example, blood group A, Cad antigens. Forssman determinants (Baker et al., 1983) and Tn epitope (Springer, 1989) . In response to our original report that HPA binding was associated with poor prognosis in breast cancer (Leathem and Brooks, 1987) , Grundbacher (1987) argued that the HPA-binding ligand might be blood group A determinant as an excess of blood group A individuals has been detected in two series of breast cancer patients (Mourali et al., 1980; Anderson and Hass, 1984) . More recently, Springer (Springer, 1988 (Springer, , 1989 has suggested that the HPA-binding ligand that appears to be associated with high metastatic potential and aggressive tumour behaviour could be Tn epitope. Tn (alpha-GalNAc-O-serine/threonine) is not normally detectable in healthy tissues, but is frequently expressed by cancer cells (e.g. Springer et al., 1975 (e.g. Springer et al., , 1985 (e.g. Springer et al., , 1986 .
In this study we have examined the expression of glycoproteins with terminal non-reducing alpha-GalNAc residues using two monoclonal antibodies -BRIC 66 (anti-alphaGalNAc) and BRIC 111 (anti-Tn) -and the lectin HPA (nominal monosaccharide specificity alpha-GalNAc). Staining protocols 1. HPA. sections were stained for HPA binding by the indirect avidin-biotin method previously described (Leathem and Brooks, 1987 (Leathem and Brooks, 1987; Brooks and Leathem, 1991 (Figure 2b , lane 2) staining was stronger and revealed more bands than HPA. BRIC 66 also recognised some, but not all, of the Tn positive bands, and these seemed to be mostly different species from those labelled by HPA, falling largely in the 20-40 kDa molecular weight range.
The Tn glycoprotein completely inhibited binding of HPA, BRIC 66 and BRIC 111 to Tn-positive lanes, but had no effect on HPA or BRIC 66 binding to blood group A. GalNAc at 0.1 M inhibited binding of BRIC 66 and HPA to both Tn and blood group A lanes, but was ineffective in blocking BRIC 111 binding to Tn. Several studies have confirmed that expression of HPA-binding glycoconjugates by breast cancer (Fenlon et al., 1987;  Leathem and Brooks, 1987; Fukutomi et al., 1989; Alam et al., 1990; Brooks and Leathem, 1991) , gastric cancer (Kakeji et al., 1991) , colorectal cancer (Schumacher et al., 1994) and prostate cancer (Shiraishi et al., 1992) is associated with both local and distant metastases and consequently poor prognosis. We have postulated that a group of as yet unidentified, HPA-binding, abnormally glycosylated molecules bearing terminal GalNAc moieties may act as biological markers of aggressive cancer behaviour (Brooks and Leathem, 1991) .
The abelrant expression of blood group antigens by cancers has been linked in several studies to prognosis (e.g. Idikio and Manickavel, 1991; Lee et al., 1991) , as has expression of Tn antigen (Springer, 1988; Springer et al., 1990) . Springer (1988 Springer ( , 1989 has suggested that the predominant structure recognised by HPA in breast (and other) cancers encompasses the Tn epitope, and that it is Tn which is responsible for the prognostic sigificance of HPA binding. Grundbacher (1987) very preliminary analysis of immunohistochemistry data and clinical/prognostic parameters yielded promising results in that node-positive cancers and those in which metastatic disease became apparent before the end of the follow-up period were more likely to be positive for expression of alpha-GalNAc glycans. Tn appears to be a functional marker of aggressive cancer behaviour possibly through its role as a cell adhesion molecule, attaching cancer cells to normal cells, in metastasis (Springer et al., 1990) . The relationship between HPA binding to cancers and aggressive biological behaviour may be, in part, through recognition of terminal alphaGalNAc on the Tn epitope. However, HPA does appear to be detecting other related ligands which share similar terminal glycans and which also may be involved, perhaps as cell adhesion molecules, in cancer metastasis. Although Tn may be associated with aggressive behaviour, it is only detectable in a minority of aggressive cancers. It seems more likely to be the GalNAc group, linked to a larger glycan (and probably not blood group A). that is associated with cancer progression.
Detailed analysis of the structure and precise function of these moieties is under intensive investigation in our laboratory. HPA reactivity of breast cancers has recently been positively correlated with amplification of the c-myc protooncogene (Fukutomi et al., 1989) , highlighting an intriguing relationship between oncogenic activity and expression of a group of aberrant GalNAc glycoconjugates which seem to be intimately involved in aggressive cancer behaviour.
